Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Can estrogens prevent neurodegeneration?

L S Schneider1, C E Finch

  • 1University of Southern California, School of Medicine, Los Angeles, USA. lschneid@hsc.usc.edu

Drugs & Aging
|August 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Higher blood lipid levels after the transition to menopause in two forager-horticulturalist populations.

Evolution, medicine, and public health·2025
Same author

Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia.

The journal of prevention of Alzheimer's disease·2023
Same author

Viewpoint: When It Comes to Lecanemab (and Donanemab), How Might We Think about 'Reasonable and Necessary'?

The journal of prevention of Alzheimer's disease·2023
Same author

Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial.

The journal of prevention of Alzheimer's disease·2022
Same author

Editorial: Aducanumab Trials EMERGE But Don't ENGAGE.

The journal of prevention of Alzheimer's disease·2022
Same author

A Polymorphism Cluster at the 2q12 locus May Predict Response to Piromelatine in Patients with Mild Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2022
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
See all related articles

Estrogen replacement therapy shows promise for improving elderly cognition and mood, potentially delaying Alzheimer's disease. Further research is needed to fully understand its neuroprotective and disease-modifying effects.

Area of Science:

  • Neuroscience
  • Gerontology
  • Endocrinology

Background:

  • Estrogen replacement therapy (ERT) demonstrates potential benefits for cognitive function and mood in older adults.
  • Recent studies link ERT to symptomatic cognitive improvements and a reduced risk or delayed onset of Alzheimer's disease (AD).
  • Basic scientific evidence supports the neuroprotective properties of estrogens.

Purpose of the Study:

  • To explore the cognitive and mood benefits of estrogen replacement therapy in the elderly.
  • To investigate the potential of estrogens in mitigating Alzheimer's disease risk and progression.
  • To delineate the specific effects of estrogens on dementia and cognitive impairment.

Main Methods:

  • Review of recent clinical studies and basic scientific evidence.

Related Experiment Videos

  • Analysis of associations between ERT use and cognitive/mood outcomes.
  • Consideration of ongoing randomized trials in Alzheimer's disease.

    • Main Results:

    • ERT is associated with short-term symptomatic cognitive enhancement in the elderly.
    • ERT may decrease the risk or delay the development of Alzheimer's disease.
    • Substantial basic science evidence supports estrogen's neuroprotective effects.

    Conclusions:

    • Estrogen replacement therapy shows significant promise for improving cognition and mood in the elderly.
    • While symptomatic benefits are evident, further research is crucial to understand ERT's disease-modifying and neuroprotective potential in dementia.
    • Sufficient knowledge exists to warrant active clinical research into the long-term effects of estrogens in elderly populations.